Innovent Biologics (HKSE:01801) Long-Term Capital Lease Obligation : HK$80 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics Long-Term Capital Lease Obligation?

Innovent Biologics's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$80 Mil.

Innovent Biologics's quarterly Long-Term Capital Lease Obligation declined from Dec. 2022 (HK$110 Mil) to Jun. 2023 (HK$95 Mil) and declined from Jun. 2023 (HK$95 Mil) to Dec. 2023 (HK$80 Mil).

Innovent Biologics's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (HK$106 Mil) to Dec. 2022 (HK$110 Mil) but then declined from Dec. 2022 (HK$110 Mil) to Dec. 2023 (HK$80 Mil).

Innovent Biologics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Innovent Biologics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Long-Term Capital Lease Obligation Chart

Innovent Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

27.31

12.13

105.78

110.20

80.31

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial										105.78	98.66	110.20	94.85	80.31

Innovent Biologics (HKSE:01801) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Innovent Biologics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics (HKSE:01801) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (HKSE:01801) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

IVBXF:USA IVBIY:USA 6IB:Germany

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Innovent Biologics (HKSE:01801) Headlines

No Headlines